RT Journal Article
T1 Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications.
A1 Garrido-Mesa, Jose
A1 Adams, Kate
A1 Galvez, Julio
A1 Garrido-Mesa, Natividad
K1 ARDS
K1 COVID-19
K1 Tetracyclines
K1 acute respiratory distress syndrome
K1 doxycycline
K1 immunomodulatory
K1 incyclinide
K1 minocycline
K1 repurposing
AB Drug repurposing can be a successful approach to deal with the scarcity of cost-effective therapies in situations such as the COVID-19 pandemic. Tetracyclines have previously shown efficacy in preclinical acute respiratory distress syndrome (ARDS) models and initial predictions and experimental reports suggest a direct antiviral activity against SARS-CoV2. Furthermore, a few clinical reports indicate their potential in COVID-19 patients. In addition to the scarcity and limitations of the scientific evidence, the effectiveness of tetracyclines in experimental ARDS has been proven extensively, counteracting the overt inflammatory reaction and fibrosis sequelae due to a synergic combination of pharmacological activities. This paper discusses the scientific evidence behind the application of tetracyclines for ARDS/COVID-19. The benefits of their multi-target pharmacology and their safety profile overcome the limitations, such as antibiotic activity and low commercial interest. Immunomodulatory tetracyclines and novel chemically modified non-antibiotic tetracyclines have therapeutic potential. Further drug repurposing studies in ARDS and severe COVID-19 are necessary.
PB Taylor & Francis
YR 2022
FD 2022-03-14
LK http://hdl.handle.net/10668/19679
UL http://hdl.handle.net/10668/19679
LA en
NO Garrido-Mesa J, Adams K, Galvez J, Garrido-Mesa N. Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications. Expert Opin Investig Drugs. 2022 May;31(5):475-482.
DS RISalud
RD Apr 4, 2025